Playback speed
10 seconds
ASCO GI 2023 Phase 3 BREAKWATER Study Safety Lead-In: Encorafenib + Cetuximab + Chemo for BRAFV600E mCRC
By
ASCO GI 2023 Conference Coverage
FEATURING
Scott Kopetz
By
ASCO GI 2023 Conference Coverage
FEATURING
Scott Kopetz
642 views
February 1, 2023
Login to view comments.
Click here to Login